{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:32:44Z","timestamp":1792661564689,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.eururo.2011.07.001","type":"journal-article","created":{"date-parts":[[2011,7,19]],"date-time":"2011-07-19T20:58:33Z","timestamp":1311109113000},"page":"784-795","source":"Crossref","is-referenced-by-count":181,"title":["Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)"],"prefix":"10.1016","volume":"60","author":[{"given":"Altaf","family":"Mangera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Erik","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prokar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giannantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Gravas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Madersbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.07.001_bib0005","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A","volume":"342","author":"Schurch","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2011.07.001_bib0015","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2003.12.007","article-title":"Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents","volume":"63","author":"Kuo","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.07.001_bib0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","article-title":"Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study","volume":"62","author":"Maria","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.07.001_bib0025","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","article-title":"Botulinum toxin a has antinociceptive effects in treating interstitial cystitis","volume":"64","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.07.001_bib0030","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coph.2004.12.006","article-title":"Botulinal neurotoxins: revival of an old killer","volume":"5","author":"Montecucco","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0035","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.eururo.2009.12.022","article-title":"Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder","volume":"57","author":"Coelho","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1464-410X.2003.04714.x","article-title":"Botulinum toxin and its applications in the lower urinary tract","volume":"93","author":"Harper","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0302-2838(03)00250-1","article-title":"Botulinum toxin as a new therapy option for voiding disorders: current state of the art","volume":"44","author":"Leippold","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0050","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","article-title":"Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence","volume":"47","author":"Grosse","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/0929867053363315","article-title":"Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin","volume":"12","author":"Maria","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.eururo.2011.07.001_bib0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00702-010-0372-0","article-title":"Comparing Botox and Xeomin for axillar hyperhidrosis","volume":"117","author":"Dressler","year":"2010","journal-title":"J Neural Transm"},{"key":"10.1016\/j.eururo.2011.07.001_bib0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1590\/S1677-55382010000100011","article-title":"Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity","volume":"36","author":"Gomes","year":"2010","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2710.2007.00835.x","article-title":"Comparing two botulinum toxin type A formulations using manufacturers\u2019 product summaries","volume":"32","author":"Wenzel","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.eururo.2011.07.001_bib0075","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ajhp\/61.suppl_6.S5","article-title":"Pharmacology of botulinum neurotoxin serotype A","volume":"61","author":"Wenzel","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.eururo.2011.07.001_bib0080","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2011.07.001_bib0085","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2007.09.034","article-title":"Neurogenic detrusor overactivity treated with english botulinum toxin A: 8-year experience of one single centre","volume":"53","author":"Del Popolo","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.urology.2009.05.097","article-title":"Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity","volume":"75","author":"Sahai","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.07.001_bib0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","article-title":"Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study","volume":"41","author":"Ehren","year":"2007","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0105","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.eururo.2010.06.035","article-title":"Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses","volume":"58","author":"Grise","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","article-title":"Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study","volume":"104","author":"Grosse","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0120","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2007.04.026","article-title":"Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence","volume":"52","author":"Schurch","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0125","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.ju.0000132152.53532.5d","article-title":"Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study","volume":"172","author":"Giannantoni","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0130","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","article-title":"Botulinum toxin-A injections into neurogenic overactive bladder\u2014to include or exclude the trigone? A prospective, randomized, controlled trial","volume":"184","author":"Abdel-Meguid","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1569-9056(11)60569-1","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic deterusor overactivity [abstract 579]","volume":"10","author":"Cruz","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.07.001_bib0140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.pmrj.2010.02.006","article-title":"Safety considerations in the use of botulinum toxins in children with cerebral palsy","volume":"2","author":"Apkon","year":"2010","journal-title":"PM R"},{"key":"10.1016\/j.eururo.2011.07.001_bib0145","unstructured":"Early communication about an ongoing safety review of Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B). US Food and Drug Administration Web site. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm070366.htm"},{"key":"10.1016\/j.eururo.2011.07.001_bib0150","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0155","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0160","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0165","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1569-9056(11)60571-X","article-title":"Botulinum toxin-A for refractory detrusor overactivity in women: a 240 patient randomised placebo controlled trial [abstract 581]","volume":"10","author":"Tincello","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.07.001_bib0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1569-9056(11)60321-7","article-title":"A randomized placebo-controlled dose finding study of onabotulinumtoixnA in men with BPH [abstract 325]","volume":"10","author":"Marberger","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.07.001_bib0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.eururo.2007.08.050","article-title":"Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption","volume":"53","author":"Silva","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-9-9","article-title":"Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment","volume":"9","author":"Silva","year":"2009","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0190","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1464-410X.2010.09841.x","article-title":"Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function","volume":"107","author":"Silva","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0195","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00365590902811537","article-title":"Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy","volume":"43","author":"Kuo","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0200","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3349\/ymj.2006.47.5.706","article-title":"Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia","volume":"47","author":"Park","year":"2006","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.eururo.2011.07.001_bib0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/00365591003649201","article-title":"Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport","volume":"44","author":"Nikoobakht","year":"2010","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0210","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/jnnp.2004.045765","article-title":"Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients","volume":"76","author":"Gallien","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eururo.2011.07.001_bib0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/nau.20946","article-title":"A pilot study of botulinum toxin for interstitial cystitis\/painful bladder syndrome","volume":"30","author":"Gottsch","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.07.001_bib0220","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0225","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/nau.20153","article-title":"Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis","volume":"25","author":"Schulte-Baukloh","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.07.001_bib0230","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11255-009-9528-y","article-title":"Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent?. Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity","volume":"41","author":"Ghalayini","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/nau.20515","article-title":"Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients","volume":"27","author":"Mascarenhas","year":"2008","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.07.001_bib0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1569-9056(11)60570-8","article-title":"Prospective randomized controlled trial compering trigonal versus trigone-sparing intradetrusor injection of botulinum toxin A for refractory idiopathic detrusor overactivity [abstract 580]","volume":"10","author":"Manecksha","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.07.001_bib0245","first-page":"3291","article-title":"Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection","volume":"13","author":"Lucioni","year":"2006","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0250","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0255","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.urology.2005.02.002","article-title":"Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics","volume":"66","author":"Kuo","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.07.001_bib0260","first-page":"276","article-title":"Botulinum toxin in high-risk BPH patients in retention","volume":"24","author":"Reddy","year":"2008","journal-title":"Indian J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0265","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.sc.3101318","article-title":"Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity","volume":"40","author":"Wyndaele","year":"2002","journal-title":"Spinal Cord"},{"key":"10.1016\/j.eururo.2011.07.001_bib0270","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.sc.3101736","article-title":"Adverse events after botulinum A toxin injection for neurogenic voiding disorders","volume":"43","author":"De Laet","year":"2005","journal-title":"Spinal Cord"},{"key":"10.1016\/j.eururo.2011.07.001_bib0275","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1464-410X.2009.08600.x","article-title":"Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction","volume":"104","author":"Pannek","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0280","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21209","article-title":"Botulinum injections for the treatment of bladder symptoms of multiple sclerosis","volume":"62","author":"Kalsi","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0285","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1464-410X.2007.06977.x","article-title":"Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction","volume":"100","author":"Akbar","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0290","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/S1677-55382008000100010","article-title":"An effective day case treatment combination for refractory neuropathic mixed incontinence","volume":"34","author":"Patki","year":"2008","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0295","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1464-410X.2006.06091.x","article-title":"What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?","volume":"97","author":"Ruffion","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0300","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000316080","article-title":"Patient-reported side effects of intradetrusor botulinum toxin type A for idiopathic overactive bladder syndrome","volume":"86","author":"Bauer","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0305","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000251175","article-title":"Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years","volume":"83","author":"Stoehrer","year":"2009","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0310","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1442-2042.2008.02016.x","article-title":"Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure","volume":"15","author":"Schulte-Baukloh","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0315","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.urology.2010.03.023","article-title":"Antibody formation following botulinum toxin type A (Dysport) injection in children with intractable bladder hyper-reflexia","volume":"76","author":"Kajbafzadeh","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.07.001_bib0320","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.eururo.2008.02.037","article-title":"Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity","volume":"53","author":"Apostolidis","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0325","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2006.01.025","article-title":"Histologic features in the urinary bladder wall affected from neurogenic overactivity\u2014a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A","volume":"50","author":"Comp\u00e9rat","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0330","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2004.07.011","article-title":"Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder","volume":"46","author":"Haferkamp","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/nau.20611","article-title":"Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units","volume":"28","author":"Cohen","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.07.001_bib0340","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/nau.20403","article-title":"Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction","volume":"26","author":"Ghalayini","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.07.001_bib0345","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1464-410X.2007.07186.x","article-title":"Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity","volume":"100","author":"Jeffery","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.07.001_bib0350","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/AOG.0b013e3181a1f5ea","article-title":"Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life","volume":"113","author":"Kessler","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0355","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0302-2838(02)00209-9","article-title":"Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease","volume":"42","author":"De Seze","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.07.001_bib0360","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.sc.3100517","article-title":"Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease","volume":"36","author":"Petit","year":"1998","journal-title":"Spinal Cord"},{"key":"10.1016\/j.eururo.2011.07.001_bib0365","first-page":"24","article-title":"Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study","volume":"71","author":"Dykstra","year":"1990","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.eururo.2011.07.001_bib0370","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.juro.2007.03.185","article-title":"The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children","volume":"178","author":"Franco","year":"2007","journal-title":"J Urol"},{"issue":"Suppl 8","key":"10.1016\/j.eururo.2011.07.001_bib0375","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/mds.20066","article-title":"Clinical comparability of marketed formulations of botulinum toxin","volume":"19","author":"Sampaio","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.eururo.2011.07.001_bib0380","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1185\/03007990903028203","article-title":"Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?","volume":"25","author":"Wohlfarth","year":"2009","journal-title":"Curr Med Res Opin"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381100738X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381100738X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:09:28Z","timestamp":1560384568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228381100738X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S030228381100738X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.07.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}